
    
      This is a randomized open label study where subjects with moderate to severe atopic
      dermatitis will roll over from the Phase 1 ASN002AD-101 and ASN002AD-201 Ph2b study and be
      randomized to receive ASN002 at 40mg, 60mg, or 80mg once daily for up to 24 months. This
      study will also characterize the pharmacokinetics of ASN002 through blood sampling from
      subjects who consent.
    
  